Table 1 Demographics of normal and HAART-treated HIV+ Nonsmokers.
From: HIV induces airway basal progenitor cells to adopt an inflammatory phenotype
Sample ID | Age | Gender/ethnicity | HIV status | Phenotype | Viral load (copies/ml) | Blood CD4 (cell # per µl) | HAART regimen |
|---|---|---|---|---|---|---|---|
1 | 22 | M (African) | − | NS | NA | NA | NA |
2 | 50 | M (African) | − | NS | NA | NA | NA |
3 | 43 | F (African) | − | NS | NA | NA | NA |
4 | 42 | F (Caucasian) | − | NS | NA | NA | NA |
5 | 53 | F (other) | + | NS | Detected, < 20 | 1106 | Elvitegravir/Cobicistat/Emtricitabine/Tenofovir alafenamide (Genvoya) |
6 | 19 | M (African) | + | NS | Detected, < 20 | 500 | Efavirenz, emtricitabine, and tenofovir disoproxil fumarate (Atripla) |
7 | 43 | M (Hispanic) | + | NS | Not detected | 1080 | Elvitegravir/Cobicistat/Emtricitabine/Tenofovir alafenamide (Genvoya) |
8 | 45 | M (African) | + | NS | Not detected | 750 | Emtricitabine, rilpivirine, and tenofovir disoproxil fumarate (Complera) |
